JNJ-88545223

DRUG2 trials

Sponsors

Janssen Cilag International, Janssen Research & Development, LLC

Conditions

Active Psoriatic ArthritisArthritis, Psoriatic

Phase 2

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

RecruitingNCT07321873

Janssen Research & Development, LLCArthritis, Psoriatic

Start: 2026-01-15End: 2027-08-02Target: 240Updated: 2026-08-28

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants with Active Psoriatic Arthritis

Not yet recruitingCTIS2025-523141-10-00

Janssen Cilag InternationalActive Psoriatic Arthritis

Target: 59Updated: 2026-03-20